Biologic & Biosimilar RA Drugs Industry Poised for Rapid Expansion, Projected to Hit $19.08 Billion by 2029
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Outlook for the Biologic & Biosimilar RA Drugs Market Heading Into 2029?
In the past few years, the market size for biologic and biosimilar ra drugs has shown a consistent growth. The market is expected to expand from $13.99 billion in 2024 to $14.57 billion in 2025, representing a compound annual growth rate (CAGR) of 4.1%. Factors such as market adoption rates, results of clinical trials, changes in market share, long-term patient outcomes, and pricing strategies can be credited for the growth during the historic period.
The market for biologic & biosimilar ra drugs is forecasted to experience robust expansion in the upcoming years, reaching a worth of $19.08 billion in 2029 with a compound annual growth rate (CAGR) of 7.0%. This expected growth during the forecast period is due to factors such as enhanced biologic drug creation, industry rivalry, healthcare reforms, patient choices, and clinical research & innovation. Some of the major trends projected for this period are an increase in biosimilar market rivalry, custom-tailored medicine and precision treatment, advancements in medication delivery methods, prioritizing safety and effectiveness, and a more patient-focused approach to healthcare.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9255&type=smp
Which Factors Are Pushing The Biologic & Biosimilar RA Drugs Market Forward?
The escalating elderly population, coupled with a rising occurrence of rheumatoid arthritis, stimulates growth in the biologics and biosimilar RA drugs market. The term “older population” denotes individuals aged 60 or above. An autoimmune disorder, rheumatoid arthritis produces a response whereby a person’s immune system targets its healthy cells, impacting the person’s joints. This condition is particularly prevalent amongst the elderly as the immune system diminishes with age. Biologics and biosimilar RA drugs offer significantly effective treatment for rheumatoid arthritis when compared to traditional medications. For instance, The World Health Organization (WHO), a UN-affiliated specialized health entity based in Switzerland, reported approximately 1 billion seniors aged 60 and above globally in 2020. Moreover, this demographic is forecasted to surge to 1.4 billion by 2030 and ultimately reach 2.1 billion by 2050. Besides, the Centers for Disease Control and Prevention, a US government public health entity, predicted that the number of adults afflicted by arthritis in the USA could rise to 78.4 million by 2040. Meanwhile, arthritis-related activity limitations might impact 34.6 million people. Consequently, the augmenting elderly population, combined with an increase in RA cases, fuels the expansion of the biologics and biosimilars RA drugs market.
Which Segment Held The Largest Share In The Biologic & Biosimilar RA Drugs Market In 2025?
The biologic & biosimilar ra drugs market covered in this report is segmented –
1) By Source: Microbial, Mammalian, Other Sources
2) By Disease: Oncology, Immunological Disorders, Cardiovascular Disorders, Hematological Disorders, Other Diseases
3) By Manufacturing: Outsourced, In-House
4) By Mode Of Purchase: Prescription Drugs, Over-The-Counter (OTC) Drugs
5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Microbial: Bacterial Sources, Fungal Sources, Yeast Sources
2) By Mammalian: Chinese Hamster Ovary (CHO) Cells, Human Embryonic Kidney (HEK) Cells, Other Mammalian Cell Lines
3) By Other Sources: Plant-Based Sources, Insect-Based Sources, Synthetic Biology Approaches
How Are Key Trends Driving Expansion In The Biologic & Biosimilar RA Drugs Industry?
The rising popularity in the biologic & biosimilar RA drugs market is greatly influenced by new innovations. To provide a more affordable option, leading companies in this sector are focused on creating biosimilar treatments like Dual Concentration Biosimilar Options. Notably, Organon, an American healthcare company, teamed up with Samsung Bioepis, a biopharmaceutical company based in South Korea, to debut HADLIMA, a Humira (adalimumab) biosimilar, in the US in July 2023. HADLIMA, offered in both high and low concentrations, aims to improve accessibility and affordability for those struggling with autoimmune diseases. The biosimilar is available at a whopping 85% discount compared to Humira, thereby facilitating improved access for patients. The Arthritis Foundation has recognized HADLIMA’s autoinjector, and a patient support program named HADLIMA For You also accompanies the biosimilar, granting educational resources and co-pay assistance. This medication is recommended for multiple health conditions including Crohn’s disease and rheumatoid arthritis. Available in both citrate-free high concentration (100 mg/mL) and citrate-inclusive low concentration (50 mg/mL) forms, HADLIMA ensures an uninterrupted continuity of care for patients.
Which Organizations Are Driving Progress In The Biologic & Biosimilar RA Drugs Industry?
Major companies operating in the biologic & biosimilar RA drugs market include Samsung BioLogics Co. Ltd., Amgen Inc., Novo Nordisk A/S, AbbVie Inc., Johnson & Johnson Services Inc., Pfizer Inc., Merck & Co. Inc., Eli Lilly and Company, Novartis AG, Bayer AG, F. Hoffmann-La Roche Ltd., AstraZeneca PLC., Teva Pharmaceutical Industries Ltd., Fresenius Se & Co. KGaA, Stada Arzneimittel AG, Boehringer Ingelheim Pharmaceuticals Inc., Gedeon Richter Plc., La Roche Ltd., Regeneron Pharmaceuticals Inc., Bristol-Myers Squibb Company, Dr. Reddy’s Laboratories Ltd., Biogen Inc., Genentech Inc., GlaxoSmithKline plc, Mylan N.V., Sandoz International GmbH, Amneal Pharmaceuticals LLC, Apotex Inc., Biocon Ltd., Coherus BioSciences Inc.
Get The Full Report Here:
Which Region Is Expected To Experience The Highest Growth In The Biologic & Biosimilar RA Drugs Industry?
North America was the largest region in the biologic & biosimilar RA drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the biologic & biosimilar RA drugs market report during the forecast period. The regions covered in the biologic & biosimilar ra drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=9255&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
